Ptger2 (EP2) and Ptger4 (EP4) mRNA was measured using qRT-PCR in CD44 hi CD8 T cells from LCMV-Arm or LCMV-CL13 infected mice at day 8 or 21 p.i. and compared to naïve (CD44 lo ) CD8 T cells from uninfected mice. Data are from three independent experiments, each with pooled mRNA from 3 mice per group for naïve and LCMV-ARM infected and 5 mice per group for LCMV-CL13 infected. Data analysis was performed by ANOVA. Error bars depict S.E.M. **P < 0.01, and ***P < 0.001. Supplementary Figure 6 Blockade of PD-L1 synergizes with PGE 2 signaling deficiency to restore the K b GP34-specifc CD8 T cell population. CD8 T cells from mice described in Figure 4 were stained with K b GP34 tetramer. Average frequency (a) and number (b) of K b GP34 + CD8 T cells are shown. Data presented were compiled from 4 experiments with a total of 13 vehicle treated WT, 12 vehicle treated EP2/4 DKO, 13 anti-PD-L1 treated WT, and 13 anti-PD-L1 treated EP2/4 DKO mice and analyzed using ANOVA. Error bars depict S.E.M. *P < 0.05, **P < 0.01.
Supplementary Figure 7 EP2/4 DKO CD8 T cells have a survival advantage. As described in Figure 6 , EP2/4 DKO and WT mice were depleted of CD4 T cells and infected with LCMV-CL13. From days 28 to 42 p.i., mice were treated every third day with either anti-PD-L1 (200µg) or PBS and given BrdU in their drinking water from day 35-42 p.i. At day 42 p.i., the GP33-and GP276-specific CD8 T cells were stained for BrdU and active caspases. The GP33-specific CD8 T cells were also stained for intracellular Bim. Bar graphs show the percentage of BrdU + or CaspGLOW + cells or MFI of Bim expression as indicated. Data were compiled from 2 experiments with a total of 7 vehicle treated WT, 6 vehicle treated EP2/4 DKO, 7 anti-PD-L1 treated WT, and 7 anti-PD-L1 treated EP2/4 DKO mice and analyzed using ANOVA. Error bars depict S.E.M. *P < 0.05.
